Free Trial

Apogee Therapeutics' (APGE) "Outperform" Rating Reiterated at Wedbush

Apogee Therapeutics logo with Medical background

Wedbush restated their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE - Free Report) in a research note released on Monday morning,RTT News reports. They currently have a $90.00 price target on the stock.

Other equities research analysts have also issued reports about the company. Citigroup began coverage on Apogee Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $95.00 price target on the stock. Guggenheim reiterated a "buy" rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a research report on Wednesday, July 2nd. Finally, BTIG Research increased their price objective on Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Monday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics presently has an average rating of "Buy" and a consensus price target of $99.00.

Get Our Latest Research Report on Apogee Therapeutics

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE traded down $8.22 during trading hours on Monday, hitting $39.24. 6,009,087 shares of the company's stock were exchanged, compared to its average volume of 587,187. Apogee Therapeutics has a 1-year low of $26.20 and a 1-year high of $76.39. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -10.90 and a beta of 1.47. The company's 50-day moving average price is $40.38 and its 200-day moving average price is $38.95.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, research analysts expect that Apogee Therapeutics will post -3.09 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Carl Dambkowski sold 10,090 shares of the business's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total value of $454,958.10. Following the sale, the insider directly owned 238,998 shares in the company, valued at $10,776,419.82. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 15,540 shares of company stock worth $653,093 in the last 90 days. Insiders own 42.77% of the company's stock.

Institutional Trading of Apogee Therapeutics

A number of institutional investors have recently modified their holdings of the company. Brooklyn Investment Group bought a new stake in Apogee Therapeutics during the first quarter worth about $42,000. GF Fund Management CO. LTD. bought a new stake in Apogee Therapeutics during the fourth quarter worth about $43,000. AlphaQuest LLC bought a new stake in Apogee Therapeutics during the first quarter worth about $43,000. GAMMA Investing LLC raised its holdings in Apogee Therapeutics by 3,560.1% during the first quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock worth $202,000 after acquiring an additional 5,269 shares in the last quarter. Finally, Optimize Financial Inc bought a new stake in Apogee Therapeutics during the fourth quarter worth about $203,000. 79.04% of the stock is currently owned by institutional investors.

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Read More

Analyst Recommendations for Apogee Therapeutics (NASDAQ:APGE)

Should You Invest $1,000 in Apogee Therapeutics Right Now?

Before you consider Apogee Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.

While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines